Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;56(1):2425066.
doi: 10.1080/07853890.2024.2425066. Epub 2024 Nov 12.

Nasopharyngeal carcinoma survival by histology in endemic and non-endemic areas

Lin-Feng Guo  1 , Jia-Geng Hong  2   3 , Run-Jie Wang  1 , Gui-Ping Chen  4 , San-Gang Wu  1
Affiliations

Nasopharyngeal carcinoma survival by histology in endemic and non-endemic areas

Lin-Feng Guo et al. Ann Med. 2024 Dec.

Abstract

Background: To investigate the prognostic implications of histology among nasopharyngeal carcinoma (NPC) using the data from a Chinese cohort and the Surveillance, Epidemiology, and End Results (SEER) database.

Methods: We included patients diagnosed with WHO II and III subtypes NPC from two independent cohorts (Xiamen [XM]-NPC cohort and SEER-NPC cohort).

Results: We identified 726 patients in the XM-NPC cohort and 1334 patients in the SEER cohort. In the XM-NPC cohort, 94 (12.9%) and 632 (87.1%) patients had WHO II and III subtypes, respectively. In the SEER-NPC cohort, 839 (62.9%) and 495 (37.1%) patients had WHO II and III subtypes, respectively. WHO II subtype patients had a higher smoking rate than the WHO III subtype (57.4% vs. 43.4%) in the XM-NPC cohort. There were no significant differences in age, gender, tumor stage, or nodal stage between the two subtypes in both cohorts. In the XM-NPC cohort, patients with the WHO II subtype had worse locoregional relapse-free survival (82.2% vs. 89.5%, p = 0.063), distant metastasis-free survival (72.4% vs. 85.9%, p = 0.028), disease-free survival (61.6% vs. 78.8%, p = 0.003), and overall survival (OS) (71.7% vs. 84.0%, p = 0.035) than those with WHO III subtype. In the SEER-NPC cohort, patients with the WHO II subtype had worse NPC-specific survival (81.1% vs. 89.4%, p < 0.001) and OS (71.6% vs. 78.8%, p < 0.001) than those with WHO III subtype. The multivariate analysis showed that histology was an independent prognostic factor associated with outcomes in both cohorts.

Conclusions: Our study demonstrates the significant influence of histological subtypes on outcomes in NPC among various populations, highlighting substantial disparities between the WHO II and WHO III subtypes.

Keywords: Chinese; Nasopharyngeal carcinoma; SEER; histology; outcome.

Plain language summary

The impact of histology on the outcomes of NPC remains controversial.We assessed the prognostic implications of histology among NPC patients using data from endemic areas of China and validated our findings using the data from the SEER database.WHO II subtype patients had a higher smoking rate than the WHO III subtype in the XM-NPC cohort.Histology is an independent factor that impacts NPC outcomes in both endemic and non-endemic areas.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Survival curves between WHO II and WHO III subtypes in the XM-NPC cohort (A, locoregional relapse-free survival; B, distant metastasis-free survival; C, disease-free survival; D, overall survival).
Figure 2.
Figure 2.
Survival curves between WHO II and WHO III subtypes in the SEER-NPC cohort (A, nasopharyngeal carcinoma-specific survival; B, overall survival).
See this image and copyright information in PMC

References

    1. Su ZY, Siak PY, Lwin YY, et al. . Epidemiology of nasopharyngeal carcinoma: current insights and future outlook. Cancer Metastasis Rev. 2024;43(3):919–939. Epub ahead of print. PMID: 38430391. doi: 10.1007/s10555-024-10176-9. - DOI - PubMed
    1. Zhang Y, Rumgay H, Li M, et al. . Nasopharyngeal Cancer Incidence and Mortality in 185 countries in 2020 and the projected burden in 2040: population-based global epidemiological profiling. JMIR Public Health Surveill. 2023;9:e49968. doi: 10.2196/49968. - DOI - PMC - PubMed
    1. Du XJ, Wang GY, Zhu XD, et al. . Refining the 8th edition TNM classification for EBV related nasopharyngeal carcinoma. Cancer Cell. 2024;42(3):464–473.e3. doi: 10.1016/j.ccell.2023.12.020. - DOI - PubMed
    1. Yuan Y, Ye F, Wu JH, et al. . Early screening of nasopharyngeal carcinoma. Head Neck. 2023;45(10):2700–2709. doi: 10.1002/hed.27466. - DOI - PubMed
    1. Xu H, Li W, Wang D.. The promising role of miRNAs in radioresistance and chemoresistance of nasopharyngeal carcinoma. Front Oncol. 2024;14:1299249. doi: 10.3389/fonc.2024.1299249. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources